Cannabis for Muscle Cramps
What evidence exists for cannabis in muscle cramps, spasticity, and related conditions.
This article is for information only and is not medical advice. Talk to a doctor before using cannabis for a health condition, and do not stop or change prescribed treatment on your own.
The only muscle-cramp use with solid evidence is nabiximols (Sativex), a standardized 1:1 THC:CBD spray, for MS spasticity—and even then, the effect is modest and mainly subjective. For everyday cramps, nocturnal charley horses, or period pain, the evidence is weak or absent. Marketing around 'indica for cramps' is folklore. Cannabis is not a replacement for physical therapy, stretching, NSAIDs, or the actual first-line treatments doctors use.
Plain-language summary
This is not medical advice. Talk to a clinician familiar with your condition before starting, stopping, or replacing any treatment.
'Muscle cramps' covers several distinct problems with very different evidence bases:
- Spasticity — chronic muscle stiffness and involuntary muscle tone increases from neurological damage (multiple sclerosis, spinal cord injury, stroke). This is what cannabis research has focused on.
- Spasms — sudden involuntary muscle contractions, often painful, common in MS and ALS.
- Ordinary cramps — the sudden calf or foot cramp at night, exercise-related cramping, period cramps. These are rarely studied with cannabis.
The strongest evidence is for nabiximols (Sativex), a standardized 1:1 THC:CBD oromucosal spray, in multiple sclerosis spasticity. Patients consistently report symptomatic improvement; objective clinician-rated measures show smaller, less consistent effects Strong evidence[1][2]. For every other type of cramping, the evidence ranges from weak to nonexistent.
What probably works (relatively speaking)
Nabiximols for MS spasticity. This is the best-studied use. Multiple randomized controlled trials and meta-analyses show that nabiximols modestly reduces patient-reported spasticity in people with MS who have not responded adequately to first-line antispasticity drugs like baclofen or tizanidine Strong evidence[1]. A 2017 National Academies report concluded there is substantial evidence that cannabinoids improve patient-reported MS spasticity symptoms Strong evidence[2]. Nabiximols is approved as a prescription medication for this indication in the United Kingdom, Germany, Spain, Canada, and other countries Strong evidence.
Important caveats:
- The effect size is modest. Roughly 30–40% of treated patients show clinically meaningful improvement compared to around 20% on placebo [1].
- Objective measures (Ashworth scale, physician-rated assessments) often do not mirror patient self-report improvements Disputed[2]. Whether this reflects real symptomatic relief that clinical scales miss, or partial placebo/unblinding effects from THC's psychoactivity, remains debated among researchers.
- The evidence is specific to the standardized 1:1 nabiximols spray, not to dispensary flower or arbitrary edibles. Extrapolation to unregulated products is reasonable but not proven in trials.
What might work
ALS-related spasticity. A randomized controlled trial of nabiximols in ALS (CANALS, 2019) found improvement in patient-reported spasticity versus placebo Weak / limited[3]. The trial was small and relatively short; these results are suggestive but not definitive.
Spinal cord injury spasticity. A small number of trials with THC, nabilone, or nabiximols suggest possible benefit, but studies are underpowered and show mixed results Weak / limited[2].
Dystonia. Case reports and small open-label studies suggest CBD or THC may reduce dystonic movements in some patients, but controlled trials are very limited and findings are inconsistent Weak / limited[4].
Parkinson's-related rigidity and dyskinesia. Results across small trials are mixed. Some suggest benefit, others show no effect or worsening Disputed[2].
Across all these conditions, sample sizes remain small, placebo effects are large, and blinding is difficult because THC produces noticeable psychoactive effects.
What doesn't have good evidence
Ordinary nocturnal leg cramps. No randomized controlled trials exist. Anecdotal reports on cannabis forums vary widely—some users report benefit, others find no effect Anecdote.
Exercise-associated muscle cramps. No trials. The leading hypothesis for these cramps is altered neuromuscular control, not dehydration or electrolyte depletion [5]. There is no clear biological reason cannabis would address the underlying mechanism, although it might reduce pain perception No data.
Menstrual cramps (dysmenorrhea). Survey data show many people use cannabis for period pain and report relief [7], but controlled trials specifically comparing cannabis to placebo for cramping (rather than general pain or mood) do not exist Anecdote. See Cannabis and Menstrual Cramps for more detail.
'Indica strains are best for cramps.' This is marketing folklore. Indica and sativa labels do not reliably predict cannabinoid or terpene content, let alone clinical effect. See Cannabis and Cannabinoid Content for more information Disputed[8].
CBD alone for cramps. Despite heavy marketing, there is no solid clinical evidence that CBD by itself relieves muscle cramps or spasticity at the doses typically sold in consumer products Weak / limited.
What we don't know
- Whether smoked or vaporized flower achieves the same effect as standardized nabiximols for spasticity. Pharmacokinetics differ substantially, and trial data comparing them are sparse.
- The optimal THC:CBD ratio for non-MS indications. The 1:1 ratio in nabiximols was a pragmatic regulatory choice, not the result of dose-finding research.
- Whether tolerance develops to the antispasticity effect during long-term use. Partial tolerance seems likely but rigorous long-term data are limited.
- Whether topical cannabinoids affect localized cramps. Mechanistically, cramps originate in the central or peripheral nervous system, not the skin, making topical absorption unlikely—but this has not been formally tested.
- Whether minor cannabinoids (CBG, THCV) or specific terpenes contribute meaningfully to cramp relief. Currently, no evidence supports this.
Comparison with standard treatments
For MS spasticity: First-line treatments are baclofen, tizanidine, gabapentin, and physical therapy. Nabiximols is positioned as add-on therapy when first-line drugs are inadequate or cause intolerable side effects like weakness or sedation. It is not clearly superior to baclofen; it is an alternative when baclofen fails or causes too much sedation.
For nocturnal leg cramps: Standard approaches are stretching, maintaining hydration, and reviewing medications that may trigger cramps (statins, diuretics). Quinine can be effective but is restricted in many countries due to cardiac and hematologic risks [5]. No comparative evidence supports cannabis for this indication.
For exercise-related cramps: Evidence-based approaches are conditioning, pacing, and possibly strong oral stimuli (pickle juice) that activate inhibitory neural reflexes [6]. Cannabis has no role in current sports medicine guidelines.
For menstrual cramps: NSAIDs (ibuprofen, naproxen) are first-line and well-supported by evidence. Hormonal contraception is second-line. Cannabis may function as an adjunct for symptom relief in some users but is not a substitute for evidence-based treatment.
Risks and trade-offs
- Psychoactive effects. THC causes intoxication, impairs driving ability, and in some users triggers anxiety or paranoia. This differs from baclofen's profile, which causes sedation and weakness without producing a high.
- Tolerance and dependence. Daily THC use leads to tolerance and, in a meaningful minority, problematic use patterns. See Cannabis Use Disorder for more detail.
- Drug interactions. CBD inhibits several cytochrome P450 enzymes and can raise levels of other medications, including some antiepileptics and anticoagulants [9]. See Cannabis and Polypharmacy Risks for details.
- Falls and cognition. In older patients with neurological disease—precisely the population most likely to use cannabis for spasticity—THC increases fall risk and may worsen cognitive symptoms [2].
- Cardiovascular effects. Acute THC use raises heart rate and may transiently elevate blood pressure; relevant for older or cardiac patients.
- Regulatory variability. Nabiximols is a prescription pharmaceutical in countries where it is approved. Dispensary cannabis is unregulated in most jurisdictions, and quality control, potency labeling, and contaminant testing vary widely.
- Driving. Cannabis impairs motor control and reaction time. Using it for spasticity does not exempt users from impaired-driving laws.
Again: this is not medical advice. If you experience recurrent muscle cramps or spasticity, talk to your doctor. Unexplained cramps can signal electrolyte imbalances, medication side effects, peripheral neuropathy, or other treatable conditions. If you have MS or another neurological condition, work with a neurologist familiar with your case before using cannabis as part of your treatment plan.
Sources
- Peer-reviewed Nielsen S, Germanos R, Weier M, et al. The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. Current Neurology and Neuroscience Reports. 2018;18(2):8.
- Government National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press; 2017.
- Peer-reviewed Riva N, Mora G, Sorarù G, et al. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurology. 2019;18(2):155-164.
- Peer-reviewed Koppel BS, Brust JCM, Fife T, et al. Systematic review: Efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(17):1556-1563.
- Peer-reviewed Allen RE, Kirby KA. Nocturnal leg cramps. American Family Physician. 2012;86(4):350-355.
- Peer-reviewed Schwellnus MP. Cause of exercise associated muscle cramps (EAMC)—altered neuromuscular control, dehydration or electrolyte depletion? British Journal of Sports Medicine. 2009;43(6):401-408.
- Peer-reviewed Slade D, Glodosky NC, Greer MC, Cuttler C. Patterns of cannabis use among self-identifying menstruating individuals. Journal of Cannabis Research. 2024;6(1):15.
- Peer-reviewed Smith CJ, Vergara D, Keegan B, Jikomes N. The phytochemical diversity of commercial Cannabis in the United States. PLOS ONE. 2022;17(5):e0267498.
- Peer-reviewed Brown JD, Winterstein AG. Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. Journal of Clinical Medicine. 2019;8(7):989.
How this page was made
Generation history
Drafted with AI assistance and checked by a separate automated fact-check pass. Not every article has been read by a person. See how articles are made.
Related
- Cannabis and Menstrual Cramps — Survey data show many users report relief, but no rigorous trials exist. NSAIDs and heat r...
- Cannabis and Polypharmacy Risks — How cannabis affects multiple-medication regimens, and which interactions are real.
- Cannabis for Hot Flashes — Popular among menopausal women, but no trials show it reduces hot flashes directly.